查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1566904

脂质奈米颗粒市场：按类型、应用和最终用户分类：2024-2033 年全球机会分析和产业预测

Lipid Nanoparticles Market By Type , By Application By End User : Global Opportunity Analysis and Industry Forecast, 2024-2033
出版日期: | 出版商: Allied Market Research | 英文 220 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2023年，全球脂质奈米颗粒市场价值为9亿美元，预计2024年至2033年复合年增长率为13.1%，到2033年将达到31亿美元。

脂质奈米颗粒（LNP）是直径在10至1000奈米之间的奈米级颗粒，主要由脂质组成。它们旨在封装药物、疫苗和遗传物质等治疗剂，保护它们免受降解并增强药物传递和功效。 LNP 可以模仿生物膜的结构，使其具有生物相容性，并且能够有效地与细胞相互作用并穿透细胞。脂质组合物通常包括磷脂质、胆固醇和其他脂质分子，有助于稳定奈米颗粒结构并控制包封物质的释放。

脂质奈米颗粒市场的成长是由癌症、糖尿病、心血管疾病、神经病变等慢性疾病盛行率上升以及对先进药物传输系统的需求迅速增长所推动的。这些疾病通常需要长期使用药物治疗，而以传统方式给药时会产生严重的副作用。 LNP 为标靶和持续递送治疗药物提供了一种有前途的替代方案，可减少全身副作用并提高患者的依从性。例如，在肿瘤学中，LNP 用于将化疗药物直接递送至癌细胞，从而最大限度地减少对健康组织的损害。

然而，基于LNP的製剂的生产和开拓在製造过程中涉及高科技和严格的品管措施，以确保奈米颗粒的稳定性和功效，导致高成本，导致市场增加，限制了市场。相反，奈米技术的进步促进了脂质奈米颗粒的开发，其稳定性更高，具有靶向递送和控释功能。这开闢了药物输送的新途径，从而实现更有效和高效的治疗性介入。例如，2022年1月，辉瑞和Acuitas Therapeutics（一家专注于开发脂质奈米颗粒（LNP）递送系统的公司，该系统可实现基于传讯RNA（mRNA）的治疗）宣布，辉瑞和Acuitas Therapeutics（一家专注于开发脂质奈米颗粒的公司） LNP）递送系统能够实现基于信使 RNA (mRNA) 的治疗，辉瑞宣布已签订开发和选择协议，可选择非独家许可 Acuitas 的 LNP 技术用于最多 10 个靶点。

分部概览

脂质奈米颗粒市场的分析分为类型、应用、最终用户和区域。依类型划分，市场分为固体脂质奈米颗粒、奈米结构脂质载体等。依用途分为治疗类和研究类。依最终用户划分，可分为製药/生技公司、学术/研究机构等。从区域来看，我们对北美、欧洲、亚太地区和拉丁美洲地区进行了分析。

主要发现

按类型划分，固体奈米颗粒细分市场在 2023 年占据最高市场占有率。

按应用划分，治疗药物领域在 2023 年占据最大市场。

从最终用户来看，製药和生技公司将在 2023 年成为市场的最大股东。

按地区划分，北美在 2023 年主导脂质奈米颗粒市场。

竞争场景

该报告可以定制。

  • 监管指引
  • 根据客户兴趣加入公司简介
  • 按国家或地区进行的附加分析 – 市场规模和预测
  • 公司简介的扩充列表
  • 历史市场资料
  • 主要参与者的详细资料（Excel格式，包括位置、联络资讯、供应商/供应商网路等）

目录

第一章简介

第 2 章执行摘要

第三章 市场状况

  • 市场定义和范围
  • 主要发现
    • 主要投资机会
    • 关键成功策略
  • 波特五力分析
  • 市场动态
    • 促进因素
    • 抑制因素
    • 机会

第四章脂质奈米颗粒市场：依类型

  • 市场概况
  • 固体脂质奈米粒
  • 奈米结构脂质载体
  • 其他的

第五章脂质奈米颗粒市场：依应用分类

  • 市场概况
  • 治疗药物
  • 研究

第六章脂质奈米颗粒市场：依最终用户分类

  • 市场概况
  • 製药和生物技术公司
  • 学术/研究机构
  • 其他的

第七章脂质奈米颗粒市场：按地区

  • 市场概况
  • 北美洲
    • 主要市场趋势和机会
    • 美国脂质奈米颗粒市场
    • 加拿大脂质奈米颗粒市场
    • 墨西哥脂质奈米颗粒市场
  • 欧洲
    • 主要市场趋势和机会
    • 德国脂质奈米颗粒市场
    • 法国脂质奈米颗粒市场
    • 英国脂质奈米颗粒市场
    • 义大利脂质奈米颗粒市场
    • 西班牙脂质奈米颗粒市场
    • 其他欧洲国家脂质奈米颗粒市场
  • 亚太地区
    • 主要市场趋势和机会
    • 日本脂质奈米粒子市场
    • 中国脂质奈米粒市场
    • 印度脂质奈米颗粒市场
    • 澳洲脂质奈米颗粒市场
    • 韩国脂质奈米颗粒市场
    • 其他亚太脂质奈米颗粒市场
  • 拉丁美洲/中东/非洲
    • 主要市场趋势和机会
    • 巴西脂质奈米颗粒市场
    • 沙乌地阿拉伯脂质奈米颗粒市场
    • 南非脂质奈米颗粒市场
    • 其他拉丁美洲/中东/非洲脂质奈米颗粒市场

第八章 竞争格局

  • 介绍
  • 关键成功策略
  • 10家主要企业产品图谱
  • 竞争对手仪表板
  • 竞争热图
  • 主要企业定位（2023年）

第九章 公司简介

  • ABP Biosciences, LLC.
  • Merck KGaA
  • Cytiva
  • CD Bioparticles
  • CordenPharma
  • Precigenome LLC.
  • Beam Therapeutics
  • Acuitas Therapeutics.
  • Helix Biotech, Inc.
  • Genevant Sciences Corporation
简介目录
Product Code: A323703

The global lipid nanoparticles market was valued at $0.9 billion in 2023, and is projected to reach $3.1 billion by 2033, growing at a CAGR of 13.1% from 2024 to 2033

Lipid nanoparticles (LNPs) are nanoscale particles ranging from 10 to 1000 nanometers in diameter, primarily composed of lipids. They are designed to encapsulate therapeutic agents such as drugs, vaccines, and genetic materials, protecting them from degradation and enhancing their delivery and efficacy. LNPs can mimic the structure of biological membranes, making them biocompatible and capable of efficiently interacting with and penetrating cells. Their lipid composition typically includes phospholipids, cholesterol, and other lipid molecules that aid in stabilizing the nanoparticle structure and controlling the release of the encapsulated cargo.

The growth of the lipid nanoparticles market is driven by rise in the prevalence of chronic diseases, such as cancer, diabetes, cardiovascular diseases, and neurological disorders, and surge in demand for advanced drug delivery systems. These conditions often require long-term treatment with drugs that have severe side effects when administered through traditional methods. LNPs offer a promising alternative by enabling targeted and sustained delivery of therapeutic agents, thereby reducing systemic side effects and improving patient compliance. In oncology, for instance, LNPs are used to deliver chemotherapeutic agents directly to tumor cells, minimizing damage to healthy tissues.

However, high cost associated with the production and development of LNP-based formulations, as the manufacturing process involves sophisticated technology and stringent quality control measures to ensure the stability and efficacy of the nanoparticles, leads to increased production costs which limit the market growth. On the contrary, advances in nanotechnology facilitated the development of lipid nanoparticles with enhanced stability, targeted delivery, and controlled release properties. This opened new avenues for drug delivery, allowing for more effective and efficient therapeutic interventions. For instance, in January 2022, Pfizer Inc. and Acuitas Therapeutics, a company focused on developing lipid nanoparticle (LNP) delivery systems to enable messenger RNA (mRNA) -based therapeutics announced that they had entered into a development and option agreement under which Pfizer will have the option to license, on a non-exclusive basis, Acuitas' LNP technology for up to 10 targets for vaccine or therapeutic development.

Segmentation Overview

The lipid nanoparticles market analysis is segmented into type, application, end user, and region. Depending on type, the market is categorized into solid lipid nanoparticles, nanostructured lipid carriers, and others. By application, it is bifurcated into therapeutics and research. As per end user, the market is classified into pharmaceutical & biotechnology companies, academic & research institutes, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

By type, the solid lipid nanoparticles segment held the highest market share in 2023.

Depending on the application, the therapeutics segment accounted for maximum share in the market in 2023.

According to end user, the pharmaceutical & biotechnology companies have been the largest shareholder in the market in 2023.

Region wise, North America dominated the lipid nanoparticles market in 2023.

Competitive Scenario

The major players operating in the lipid nanoparticles market include ABP Biosciences, LLC., Merck KGaA, Cytiva, CD Bioparticles, CordenPharma, Precigenome LLC., Beam Therapeutics, Acuitas Therapeutics, GENEVANT SCIENCES CORPORATION, and Helix Biotech, Inc. Other players in lipid nanoparticles market includes Arbutus Biopharma, and Croda International Plc. These players have adopted several strategies, including mergers & acquisitions, collaborations, product innovation & diversification, and partnerships, to maintain their foothold in the market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Type

  • Solid Lipid Nanoparticles
  • Nanostructured Lipid Carriers
  • Others

By Application

  • Therapeutics
  • Research

By End User

  • Pharmaceutical and Biotechnology Companies
  • Academic and Research Institutes
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • ABP Biosciences, LLC.
    • Merck KGaA
    • Cytiva
    • CD Bioparticles
    • CordenPharma
    • Precigenome LLC.
    • Beam Therapeutics
    • Acuitas Therapeutics.
    • Helix Biotech, Inc.
    • Genevant Sciences Corporation

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: LIPID NANOPARTICLES MARKET, BY TYPE

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Type
  • 4.2. Solid Lipid Nanoparticles
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. Nanostructured Lipid Carriers
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country
  • 4.4. Others
    • 4.4.1. Key Market Trends, Growth Factors and Opportunities
    • 4.4.2. Market Size and Forecast, By Region
    • 4.4.3. Market Share Analysis, By Country

CHAPTER 5: LIPID NANOPARTICLES MARKET, BY APPLICATION

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By Application
  • 5.2. Therapeutics
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Research
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country

CHAPTER 6: LIPID NANOPARTICLES MARKET, BY END USER

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By End User
  • 6.2. Pharmaceutical And Biotechnology Companies
    • 6.2.1. Key Market Trends, Growth Factors and Opportunities
    • 6.2.2. Market Size and Forecast, By Region
    • 6.2.3. Market Share Analysis, By Country
  • 6.3. Academic And Research Institutes
    • 6.3.1. Key Market Trends, Growth Factors and Opportunities
    • 6.3.2. Market Size and Forecast, By Region
    • 6.3.3. Market Share Analysis, By Country
  • 6.4. Others
    • 6.4.1. Key Market Trends, Growth Factors and Opportunities
    • 6.4.2. Market Size and Forecast, By Region
    • 6.4.3. Market Share Analysis, By Country

CHAPTER 7: LIPID NANOPARTICLES MARKET, BY REGION

  • 7.1. Market Overview
    • 7.1.1 Market Size and Forecast, By Region
  • 7.2. North America
    • 7.2.1. Key Market Trends and Opportunities
    • 7.2.2. Market Size and Forecast, By Type
    • 7.2.3. Market Size and Forecast, By Application
    • 7.2.4. Market Size and Forecast, By End User
    • 7.2.5. Market Size and Forecast, By Country
    • 7.2.6. U.S. Lipid Nanoparticles Market
      • 7.2.6.1. Market Size and Forecast, By Type
      • 7.2.6.2. Market Size and Forecast, By Application
      • 7.2.6.3. Market Size and Forecast, By End User
    • 7.2.7. Canada Lipid Nanoparticles Market
      • 7.2.7.1. Market Size and Forecast, By Type
      • 7.2.7.2. Market Size and Forecast, By Application
      • 7.2.7.3. Market Size and Forecast, By End User
    • 7.2.8. Mexico Lipid Nanoparticles Market
      • 7.2.8.1. Market Size and Forecast, By Type
      • 7.2.8.2. Market Size and Forecast, By Application
      • 7.2.8.3. Market Size and Forecast, By End User
  • 7.3. Europe
    • 7.3.1. Key Market Trends and Opportunities
    • 7.3.2. Market Size and Forecast, By Type
    • 7.3.3. Market Size and Forecast, By Application
    • 7.3.4. Market Size and Forecast, By End User
    • 7.3.5. Market Size and Forecast, By Country
    • 7.3.6. Germany Lipid Nanoparticles Market
      • 7.3.6.1. Market Size and Forecast, By Type
      • 7.3.6.2. Market Size and Forecast, By Application
      • 7.3.6.3. Market Size and Forecast, By End User
    • 7.3.7. France Lipid Nanoparticles Market
      • 7.3.7.1. Market Size and Forecast, By Type
      • 7.3.7.2. Market Size and Forecast, By Application
      • 7.3.7.3. Market Size and Forecast, By End User
    • 7.3.8. UK Lipid Nanoparticles Market
      • 7.3.8.1. Market Size and Forecast, By Type
      • 7.3.8.2. Market Size and Forecast, By Application
      • 7.3.8.3. Market Size and Forecast, By End User
    • 7.3.9. Italy Lipid Nanoparticles Market
      • 7.3.9.1. Market Size and Forecast, By Type
      • 7.3.9.2. Market Size and Forecast, By Application
      • 7.3.9.3. Market Size and Forecast, By End User
    • 7.3.10. Spain Lipid Nanoparticles Market
      • 7.3.10.1. Market Size and Forecast, By Type
      • 7.3.10.2. Market Size and Forecast, By Application
      • 7.3.10.3. Market Size and Forecast, By End User
    • 7.3.11. Rest of Europe Lipid Nanoparticles Market
      • 7.3.11.1. Market Size and Forecast, By Type
      • 7.3.11.2. Market Size and Forecast, By Application
      • 7.3.11.3. Market Size and Forecast, By End User
  • 7.4. Asia-Pacific
    • 7.4.1. Key Market Trends and Opportunities
    • 7.4.2. Market Size and Forecast, By Type
    • 7.4.3. Market Size and Forecast, By Application
    • 7.4.4. Market Size and Forecast, By End User
    • 7.4.5. Market Size and Forecast, By Country
    • 7.4.6. Japan Lipid Nanoparticles Market
      • 7.4.6.1. Market Size and Forecast, By Type
      • 7.4.6.2. Market Size and Forecast, By Application
      • 7.4.6.3. Market Size and Forecast, By End User
    • 7.4.7. China Lipid Nanoparticles Market
      • 7.4.7.1. Market Size and Forecast, By Type
      • 7.4.7.2. Market Size and Forecast, By Application
      • 7.4.7.3. Market Size and Forecast, By End User
    • 7.4.8. India Lipid Nanoparticles Market
      • 7.4.8.1. Market Size and Forecast, By Type
      • 7.4.8.2. Market Size and Forecast, By Application
      • 7.4.8.3. Market Size and Forecast, By End User
    • 7.4.9. Australia Lipid Nanoparticles Market
      • 7.4.9.1. Market Size and Forecast, By Type
      • 7.4.9.2. Market Size and Forecast, By Application
      • 7.4.9.3. Market Size and Forecast, By End User
    • 7.4.10. South Korea Lipid Nanoparticles Market
      • 7.4.10.1. Market Size and Forecast, By Type
      • 7.4.10.2. Market Size and Forecast, By Application
      • 7.4.10.3. Market Size and Forecast, By End User
    • 7.4.11. Rest of Asia-Pacific Lipid Nanoparticles Market
      • 7.4.11.1. Market Size and Forecast, By Type
      • 7.4.11.2. Market Size and Forecast, By Application
      • 7.4.11.3. Market Size and Forecast, By End User
  • 7.5. LAMEA
    • 7.5.1. Key Market Trends and Opportunities
    • 7.5.2. Market Size and Forecast, By Type
    • 7.5.3. Market Size and Forecast, By Application
    • 7.5.4. Market Size and Forecast, By End User
    • 7.5.5. Market Size and Forecast, By Country
    • 7.5.6. Brazil Lipid Nanoparticles Market
      • 7.5.6.1. Market Size and Forecast, By Type
      • 7.5.6.2. Market Size and Forecast, By Application
      • 7.5.6.3. Market Size and Forecast, By End User
    • 7.5.7. Saudi Arabia Lipid Nanoparticles Market
      • 7.5.7.1. Market Size and Forecast, By Type
      • 7.5.7.2. Market Size and Forecast, By Application
      • 7.5.7.3. Market Size and Forecast, By End User
    • 7.5.8. South Africa Lipid Nanoparticles Market
      • 7.5.8.1. Market Size and Forecast, By Type
      • 7.5.8.2. Market Size and Forecast, By Application
      • 7.5.8.3. Market Size and Forecast, By End User
    • 7.5.9. Rest of LAMEA Lipid Nanoparticles Market
      • 7.5.9.1. Market Size and Forecast, By Type
      • 7.5.9.2. Market Size and Forecast, By Application
      • 7.5.9.3. Market Size and Forecast, By End User

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top Winning Strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top Player Positioning, 2023

CHAPTER 9: COMPANY PROFILES

  • 9.1. ABP Biosciences, LLC.
    • 9.1.1. Company Overview
    • 9.1.2. Key Executives
    • 9.1.3. Company Snapshot
    • 9.1.4. Operating Business Segments
    • 9.1.5. Product Portfolio
    • 9.1.6. Business Performance
    • 9.1.7. Key Strategic Moves and Developments
  • 9.2. Merck KGaA
    • 9.2.1. Company Overview
    • 9.2.2. Key Executives
    • 9.2.3. Company Snapshot
    • 9.2.4. Operating Business Segments
    • 9.2.5. Product Portfolio
    • 9.2.6. Business Performance
    • 9.2.7. Key Strategic Moves and Developments
  • 9.3. Cytiva
    • 9.3.1. Company Overview
    • 9.3.2. Key Executives
    • 9.3.3. Company Snapshot
    • 9.3.4. Operating Business Segments
    • 9.3.5. Product Portfolio
    • 9.3.6. Business Performance
    • 9.3.7. Key Strategic Moves and Developments
  • 9.4. CD Bioparticles
    • 9.4.1. Company Overview
    • 9.4.2. Key Executives
    • 9.4.3. Company Snapshot
    • 9.4.4. Operating Business Segments
    • 9.4.5. Product Portfolio
    • 9.4.6. Business Performance
    • 9.4.7. Key Strategic Moves and Developments
  • 9.5. CordenPharma
    • 9.5.1. Company Overview
    • 9.5.2. Key Executives
    • 9.5.3. Company Snapshot
    • 9.5.4. Operating Business Segments
    • 9.5.5. Product Portfolio
    • 9.5.6. Business Performance
    • 9.5.7. Key Strategic Moves and Developments
  • 9.6. Precigenome LLC.
    • 9.6.1. Company Overview
    • 9.6.2. Key Executives
    • 9.6.3. Company Snapshot
    • 9.6.4. Operating Business Segments
    • 9.6.5. Product Portfolio
    • 9.6.6. Business Performance
    • 9.6.7. Key Strategic Moves and Developments
  • 9.7. Beam Therapeutics
    • 9.7.1. Company Overview
    • 9.7.2. Key Executives
    • 9.7.3. Company Snapshot
    • 9.7.4. Operating Business Segments
    • 9.7.5. Product Portfolio
    • 9.7.6. Business Performance
    • 9.7.7. Key Strategic Moves and Developments
  • 9.8. Acuitas Therapeutics.
    • 9.8.1. Company Overview
    • 9.8.2. Key Executives
    • 9.8.3. Company Snapshot
    • 9.8.4. Operating Business Segments
    • 9.8.5. Product Portfolio
    • 9.8.6. Business Performance
    • 9.8.7. Key Strategic Moves and Developments
  • 9.9. Helix Biotech, Inc.
    • 9.9.1. Company Overview
    • 9.9.2. Key Executives
    • 9.9.3. Company Snapshot
    • 9.9.4. Operating Business Segments
    • 9.9.5. Product Portfolio
    • 9.9.6. Business Performance
    • 9.9.7. Key Strategic Moves and Developments
  • 9.10. Genevant Sciences Corporation
    • 9.10.1. Company Overview
    • 9.10.2. Key Executives
    • 9.10.3. Company Snapshot
    • 9.10.4. Operating Business Segments
    • 9.10.5. Product Portfolio
    • 9.10.6. Business Performance
    • 9.10.7. Key Strategic Moves and Developments